Misonix Incorporated Release: Novel BoneScalpel Technique Published In Operative Neurosurgery

FARMINGDALE, N.Y., Dec. 2, 2014 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, announces a new clinical publication entitled, “Ultrasonic Total Uncinectomy: A Novel Technique for Complete Anterior Decompression of Cervical Nerve Roots,” by Peyman Pakzaban, MD, Houston, Texas.

This clinical article has been published in the December issue of Operative Neurosurgery. “I am excited with being able to share my experiences with my colleagues on my use of the BoneScalpel in performing an Ultrasonic Total Uncinectomy (“UTU”) during anterior cervical discectomy fusion (“ACDF”) procedures,” said Dr. Pakzaban.

The Misonix BoneScalpel is an ultrasonic device providing surgeons with a bone-cutting instrument that provides a clean, controlled bone incision and removal that is also soft tissue sparing.

Dr. Pakzaban continued, “In my experience and practice, the UTU has been proven to be a safe and effective technique for complete decompression of the cervical nerve root during ACDF procedures.”

Along with the surgical technique, this clinical article also details Dr. Pakzaban’s experience with thirty-eight patients undergoing a single- or multi-level UTU in conjunction with an ACDF procedure. These patients were followed up on at one and six week intervals and were tracked for neck pain, radiculopathy and myelopathy. The article also reports average blood loss, surgery time and length of hospital stay.

In his study, Dr. Pakzaban encountered no vertebral artery injuries or dural lacerations. Dr. Pakzaban concluded, “With unique surgical technologies, like the BoneScalpel, spine surgeons are now able to perform precise procedures, like the Uncinectomy, with a reduced fear of injury to soft tissue or the vertebral artery.”

“We are encouraged by Dr. Pakzaban’s technical article and study results,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. “This study adds to the growing body of published clinical evidence and confirms the unique value that the BoneScalpel brings to spine surgeons and their patients.”

The complete article can be downloaded from Operative Neurosurgery at: http://journals.lww.com/neurosurgery/Fulltext/2014/12001/Ultrasonic_Total_Uncinectomy___A_Novel_Technique.5.aspx

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/novel-bonescalpel-technique-published-in-operative-neurosurgery-300003135.html

SOURCE Misonix, Inc.